Go Pro
→ They're not buying gold. They're buying this. (From Behind the Markets) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$403.04
-1.0%		$410.72
$288.00
▼
$447.03
$217.90B0.412.76 million shs3.51 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$10.46
-1.3%		$9.09
$6.20
▼
$11.97
$1.73B2.434.79 million shs4.02 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
-3.38%+0.30%-7.04%+8.85%+36.44%
Novavax, Inc. stock logo
NVAX
Novavax
-1.94%0.00%+4.74%+8.83%+11.58%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$403.04
-1.0%		$410.72
$288.00
▼
$447.03
$217.90B0.412.76 million shs3.51 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$10.46
-1.3%		$9.09
$6.20
▼
$11.97
$1.73B2.434.79 million shs4.02 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
-3.38%+0.30%-7.04%+8.85%+36.44%
Novavax, Inc. stock logo
NVAX
Novavax
-1.94%0.00%+4.74%+8.83%+11.58%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.33
Hold$385.25-4.41% Downside
Novavax, Inc. stock logo
NVAX
Novavax
2.33
Hold$14.0033.84% Upside

Current Analyst Ratings Breakdown

Latest AMGN and NVAX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/28/2026
Amgen Inc. stock logo
AMGN
Amgen
Scotiabank logo
Scotiabank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$450.00 ➝ $500.00
9/23/2026
Amgen Inc. stock logo
AMGN
Amgen
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold$410.00
9/23/2026
Amgen Inc. stock logo
AMGN
Amgen
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
9/17/2026
Amgen Inc. stock logo
AMGN
Amgen
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$430.00
9/10/2026
Amgen Inc. stock logo
AMGN
Amgen
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold$445.00 ➝ $425.00
9/8/2026
Amgen Inc. stock logo
AMGN
Amgen
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$450.00
9/8/2026
Amgen Inc. stock logo
AMGN
Amgen
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$400.00
9/4/2026
Amgen Inc. stock logo
AMGN
Amgen
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$400.00 ➝ $435.00
8/20/2026
Amgen Inc. stock logo
AMGN
Amgen
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$427.00 ➝ $457.00
8/19/2026
Amgen Inc. stock logo
AMGN
Amgen
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$362.00
8/6/2026
Novavax, Inc. stock logo
NVAX
Novavax
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$36.75B5.93$32.32 per share12.47$16.08 per share25.06
Novavax, Inc. stock logo
NVAX
Novavax
$1.12B1.54$3.40 per share3.08($0.79) per share-13.24
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$7.71B$16.0925.0516.483.0422.95%124.14%13.18%11/3/2026 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
$440.30M-$1.52N/AN/AN/A-59.87%-14.82%-13.35%11/5/2026 (Estimated)

Latest AMGN and NVAX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Novavax, Inc. stock logo
NVAX
Novavax
-$0.3798-$0.32+$0.0598-$0.32$52.51 million$56.70 million
8/4/2026Q2 2026
Amgen Inc. stock logo
AMGN
Amgen
$5.62$6.29+$0.67$4.37$9.43 billion$10.05 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$10.082.49%+8.27%62.65%14 Years
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A

Latest AMGN and NVAX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/30/2026
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.522.29%8/21/20268/21/20269/11/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
4.44
1.37
1.13
Novavax, Inc. stock logo
NVAX
Novavax
N/A
2.33
2.30

Institutional Ownership

CompanyInstitutional Ownership
Amgen Inc. stock logo
AMGN
Amgen
76.50%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%

Insider Ownership

CompanyInsider Ownership
Amgen Inc. stock logo
AMGN
Amgen
0.85%
Novavax, Inc. stock logo
NVAX
Novavax
1.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
31,500540.63 million536.04 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
749164.95 million162.31 millionOptionable

Recent News About These Companies

3 Overrated Stocks We Approach with Caution
October 2 at 5:47 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/3-overrated-stocks-approach-caution-081403062.html
Novavax (NVAX) Rises As Market Takes a Dip: Key Facts
September 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/novavax-nvax-rises-market-takes-204505497.html
Novavax (NVAX) Rises As Market Takes a Dip: Key Facts
September 28, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2997037/novavax-nvax-rises-as-market-takes-a-dip-key-facts?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_6-2997037
Novavax (NVAX)
September 28, 2026  |  es.investing.comhttps://es.investing.com/equities/novavax
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
September 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/novavax-inc-nvax-trending-stock-120005356.html
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
September 28, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2996475/novavax-inc-nvax-is-a-trending-stock-facts-to-know-before-betting-on-it?cid=cs-stocknewsapi-ft-fundamental_analysis|most_searched_stocks-2996475
Novavax otwiera nowy rozdział. Czy Matrix-M i partnerstwa z gigantami mogą rozpędzić NVAX?
September 25, 2026  |  jaw.plJ
Novavax (NASDAQ:NVAX) Stock Breaks Above Two Hundred Day Moving Average - Here's Why
September 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-novavax-nasdaq-nvax-stock-breaks-above-two-hundred-day-moving-average-heres-why-2026-09-25/
3 Volatile Stocks with Questionable Fundamentals
September 21, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/3-volatile-stocks-questionable-fundamentals-093425365.html
Novavax stock gains as Q2 2026 revenue rises and vaccine focus deepens
September 20, 2026  |  ad-hoc-news.deA
Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know
September 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/novavax-nvax-beats-stock-market-214504647.html
Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know
September 18, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2992320/novavax-nvax-beats-stock-market-upswing-what-investors-need-to-know?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_6-2992320
Novavax (NVAX) Soars 7.0%: Is Further Upside Left in the Stock?
September 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/novavax-nvax-soars-7-0-074500823.html
Novavax (NVAX) Soars 7.0%: Is Further Upside Left in the Stock?
September 18, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2991718/novavax-nvax-soars-7-0-is-further-upside-left-in-the-stock?cid=cs-stocknewsapi-ft-fundamental_analysis|daily_price_change_5%-2991718
Novavax (NASDAQ:NVAX) Shares Up 8% - Time to Buy?
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-novavax-nasdaq-nvax-shares-up-8-time-to-buy-2026-09-17/
Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher
September 17, 2026  |  247wallst.comhttps://247wallst.com/investing/2026/09/17/moderna-climbs-6-as-cancer-vaccine-trade-extends-a-137-month-biontech-and-novavax-edge-higher/
Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher
September 17, 2026  |  247wallst.comhttps://247wallst.com/investing/2026/09/17/moderna-climbs-6-as-cancer-vaccine-trade-extends-a-137-month-biontech-and-novavax-edge-higher/?utm_source=snapi
Squarepoint Ops LLC Invests $1.26 Million in Novavax, Inc. $NVAX
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-squarepoint-ops-llc-invests-126-million-in-novavax-inc-nvax-2026-09-17/
Do Novavax’s (NVAX) New Partnerships Offset Policy Risks From The Protecting Approved Care Act?
September 16, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novavax-nvax-partnerships-offset-policy-051305726.html
Novavax (NVAX) Could Be 32% Above Fair Value On Medicare Policy Fears
September 16, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novavax-nvax-could-32-above-071252123.html
Astrana Health, Clover Health, Alignment Healthcare, and Novavax Stocks Trade Down, What You Need To Know
September 15, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NVAX/pressreleases/4622103/astrana-health-clover-health-alignment-healthcare-and-novavax-stocks-trade-down-what-you-need-to-know/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Stacks of coins rising on a desk beside a computer with an upward stock chart, with a blurred city skyline behind.
3 Dividend Kings to Buy While They’re Still Beaten Down
By Thomas Hughes | September 14, 2026
Amgen logo displayed on a glass panel in a laboratory setting with microscopes and sample vials.
Amgen Drops 10% on a Trial It Didn't Even Run
By Chris Markoch | September 11, 2026
Amgen stock logo

Amgen NASDAQ:AMGN

$403.04 -4.23 (-1.04%)
Closing price 04:00 PM Eastern
Extended Trading
$403.55 +0.51 (+0.13%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Novavax stock logo

Novavax NASDAQ:NVAX

$10.46 -0.14 (-1.32%)
Closing price 04:00 PM Eastern
Extended Trading
$10.45 -0.01 (-0.06%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas